USA

The latest milestone advances the company’s second clinical-stage therapeutic candidate and marks the first clinical programme built using its proprietary Au-HALO™ liver-targeting delivery technology and siRNA platform.

AbCellera will oversee discovery and early-stage development activities, while Vertex will finance all research and development costs.

Amylyx developed the education initiative after researching the PBH patient community.

eyonis LCS is a Software as a Medical Device that uses AI to assist clinicians in detecting and diagnosing lung cancer during screening workflows.

Under the agreement, the companies will advance Sail’s lead programme, SAIL-0839, which is being developed to engineer CD4+ and CD8+ T-cells inside the body to treat immune-mediated diseases.

RushData aims to address these bottlenecks by bringing antibody expression, binding analysis and early developability profiling into a standardised workflow.

The approval makes Simtriyo the first norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) for ADHD and gives Otsuka what Jefferies analysts described as its “next major CNS launch.”

The approval provides consumers with an additional non-prescription option for managing common types of temporary pain.

Lytenava contains bevacizumab, an anti-vascular endothelial growth factor (anti-VEGF) antibody that inhibits the growth of abnormal blood vessels that can damage the retina.

The agreements are nonexclusive and cover Aspen Pharmacare, Quality Chemical Industries and UCL Kenya in sub-Saharan Africa, as well as Aurobindo, Cipla, Emcure and Viatris in India.